As we head into the new year, equity markets couldn’t be on a stronger note. Markets appear to have pushed past the concerns, taking cues from interest rate direction, global and domestic growth & demand, stable government and more. 

So are markets on firm footing to shoot high in 2024 as well?

Equity Outlook 2024

As we see the equity outlook 2024 will be a year of frontloaded returns. A healthy correction could be underway in the second half, led by one or more of the following broad factors:

  • Expectations vs reality on economic growth and interest rates, both globally and at home
  • Slowing Govt. capex in Budget 2024 (July) to achieve fiscal deficit targets, and the impact on capex-centric and manufacturing companies
  • Valuation excesses and euphoria in many pockets, including PSUs with narratives scoring over numbers

In our view, 2024 will be a year to play it safe, avoid excessive risks of relying on narratives in sectors or stocks, and be more realistic in terms of further upside from here. Here’s a detailed explanation of how we see equity markets behaving over the course of 2024.

A rewind of 2023

A look back on what shaped markets in 2023 will help set the equity outlook 2024. The year 2023 didn’t start with optimism against the backdrop of US rate hikes, concerns around a US recession and continued selling by FIIs. 

The first trigger came after the Silicon Valley Bank crisis in the US in March 2023, which set expectations of a pause in rate hikes by the US Fed. Markets turned south as the US Fed remained hawkish and US 10-year yields hit 5%. 

That panic marked bottom for both equities and bonds. Equity and debt markets made a stellar comeback in the last two months of 2023 as the Fed struck a U-turn on rates in its December policy meeting. Meanwhile, forecasts of a US recession didn’t come true as the economy showed significant resilience. 

Our markets couldn’t help but dance to the tunes of US outcomes and aggressive FII selling. But we also saw the rise of Indian investor who absorbed the entire FII selling, including the large blocks of selling by Private Equity majors. This large domestic flow also helped our market to sustain valuations at the upper end of the PE band despite adverse global circumstances for a large part of 2023. 

In our equity outlook 2023, and over the course of last year as well, we had advised you to look outside of Index, as we expected index returns to be capped. We placed an emphasis on auto and ancillaries, pharmaceutical API, cement, consumer durables and textiles. This bore true as the year played out. 

Let’s take a quick glance through the outperformers and underperformers of 2023 to set the context for 2024.

The biggest underperformer of 2023 was the heavyweight banking sector with a nearly 10% underperformance compared to the Nifty. After a stellar rally in 2022, banking heavyweights paused in 2023 as deposit rates weighed on their margins; the HDFC group merger, too, weighed. IT services managed to match Nifty returns but couldn’t do further lifting of the Nifty as large caps lagged mid-sized players in performance. IT has started 2024 on a highly positive note, though, calling an end to the pessimistic outlook. 

The smallcap segment significantly underperformed the Nifty, with -40% returns between 2018-2020 (pre-Covid) when the Nifty delivered just about positive returns. At the beginning of 2023, the Nifty Smallcap 100 was at the same level as it was in 2018. The index has since significantly caught up in 2023, delivering 50% returns over the pre-Covid peak. 

This was also one of the opportunities we had highlighted in our 2023 outlook, and we had specifically issued a smallcap fund recommendation just before the smallcap rally really took off. There may be a little more of catch up remaining in the early part of 2024. Here’s a quick look into the chart of Nifty Small cap 100 Index.

Source: NSE India, Nifty Small cap 100 fact sheet

This sector was on the back foot for nearly a decade and a half – ever since the global financial crisis. But 2023 marked a phenomenal comeback for the sector due to robust demand. This sector’s recovery also has significant spill-over effect on demand for cement, housing finance, home improvement, and so on, as it is one of the key components of the capex in the economy. The upbeat sentiment in the sector is reminiscent of the 2007 heydays; the top index constituent, DLF, is back past its IPO price after 14 years. 

Capital goods is another sector that surprised on earnings, as their exports also fired led by clean energy transition globally (US Inflation reduction act, Europe energy investments).  Companies engaged in turbines, compressors, transformers, drilling & mining equipment, and consumables stole the show with stellar earnings performance. We had called out during our 2023 outlook that the story may gather momentum during the year, including exports. 

PSUs, on the other hand, had 3 factors driving stock price – ignored valuations, global capacity constraints in sectors like defence, and upbeat sentiment supported by Govt. capex. Sentiment is the biggest factor among all playing out now and so this sector may prove to be deceptive for investors trying to catch late. 

What lies ahead in 2024?

With this background, let’s get into what could play out over 2024. We have broken this down on the following lines:

  • Broad market perspective
  • Nifty valuations and market levels

With markets breaking out globally (US, Europe, Japan, India, Brazil) and sentiment upbeat, there is no reason to go on the back foot immediately. A better phrase to say about equities now is “there is a bull market everywhere!” (ex-China). 

The pitch looks clean and good ahead of two main factors, both slated towards the middle of the calendar year. 

  • The first rate cut from the US Fed. A US soft-landing combined with rate cuts playing out as expected is the most desirable outcome for every asset class that the dollar is flowing into. It appears that all asset classes are currently priced for this outcome.
  • Our own general elections, with expectations of continued stability of the current government. Expectations of continued pause on rates or a rate cut by the RBI are also being priced in.

However, expectations will have to play out as per template for markets to hold gains and end on a positive note in 2024. Even minor disappointments can lead to meaningful corrections. 

For us, the implication of US economy macros is mainly on sentiment and flows, be it FII or FDI. India’s inclusion in MSCI bond index and potentially higher equity allocations in the Emerging Market (EM) basket, could lend some sort of balancing act.  

More important for us would be Budget 2024 post general elections (in July) that may serve as a test for capex-dependent sectors as to what extent Govt. can continue the heavy lifting  (after 2 consecutive years of 30% and a 35% growth in allocation) without deviating from the planned fiscal consolidation path. An adverse outcome on this front in Budget could disappoint markets unless private sector capex rises to the occasion to compensate. 

At this time, therefore, all we can say is that markets are setting up for a good first half until the time expectations need to materialise. Based on how reality pans out, on global and domestic macros at that point, and market valuations, we may see markets react by staying on course or correcting. 

By now, the Nifty has completed ~80% rally (16% CAGR) from the pre-Covid level. This is well-justified by a 100% growth in earnings (doubling of EPS) and there is valuation comfort of a contracting PE multiple (~25 times pre-Covid to 22 times now). This happened at a time when the economy itself took 2 years to recover back to its pre-Covid GDP levels. 

See the graph below, on the Nifty EPS. The take off in earnings has come after 7 years of stagnancy. This has come by in the aftermath of Covid, especially the wild jump in FY22, and the continuity of growth from there. 

There is one key point to note here – the bulk of the EPS growth is contributed by cyclicals that were putting a poor show until FY20 and then emerged as outliers post Covid. Cyclicals with 24.5% combined weight grew their PAT ~4X in 4 years, at >40% CAGR. Here’s a quick glimpse into the outliers, category wise, with their combined weight in Nifty 50:

Why is this important? The higher contribution of earnings from cyclicals limits room for further expansion in PE multiples. Therefore, current valuations at 22 times FY24 earnings and 19 times FY25 estimated earnings are quite fair in our view. 

We expect the market to hover around 18 to 20 times FY25 estimated earnings on the lower and upper bands, respectively, as highlighted in table below.

An outcome other than soft landing in US may lead to lower than the 15% expected earnings growth. The lower band may be breached by 5-10% as global cyclicals may take a hit on their earnings. 

To summarize the broad market and valuation perspectives: 

  • The current equity market sentiment is positive, in light of expectations on US interest rates and domestic political outcome. 
  • With this, the year could turn out to be one where returns are frontloaded in the first half and see an uncertain second half. 
  • The second half could be shaped up by how the US economy fares, how rate cuts both in the US and at home pan out, and what’s in store in our Budget 2024. 

Also, its beyond our guess if anything unexpected could crop up in 2024; like the Russia- Ukraine Crisis in early 2022 and the Silicon Valley Bank crisis in early 2023 gave a bit of a hard knock to markets. 

Themes to play and avoid in 2024

2024 will be a year to pay it safe and not take excessive risks. Here is where we see opportunities in 2024 and highlight what to steer clear of.

Banking sector valuations are attractive considering their growth tailwinds and the sedate 2023 returns as we noted above. The IT sector has started 2024 on a positive note. Riding safe can work in favour of investors considering the stretched valuations down the order in most other pockets. Large caps in financial, IT services, pharmaceuticals, and consumption could provide valuation comfort combined with decent growth. 

One can therefore play the private capex recovery through financials, especially corporate lenders, which are trading at reasonable valuations at this point of time. Corporate banks in large and mid-sized space are doing well while tight liquidity conditions are giving them a better yield on the corporate book. Lower yield was hurting them in past and was forcing banks to chase retail lending; better yields on corporate book can therefore be highly rewarding. 

Private sector capex in sectors like manufacturing will be largely funded by borrowings than FDI as these companies can take debt based on their earnings and prevents dilution for promoters. Besides, they borrow to fund their working capital requirements as well.

Outside of banks, to play the capex theme directly, it would be safer to stick to those with significant and proven execution capabilities.

With all growth pockets seeing skyrocketing valuations, consumption as a pocket looks better from the point of view of balance sheet, return ratios and cash flows. Consumption is also one pocket with significant long-term growth tailwinds in a growing economy of large size like India. 

These are businesses with secular growth prospects, healthy balance sheet and superior RoCE profile and look a far better place than cyclicals at this point of time. Large-cap consumer stocks, while doling out a temporary hit owing to higher valuation at entry, are still unlikely to take you for a ride on account of balance sheet or profitability issues which cyclicals are wont to do. 

Here’s a quick comparison of the Nifty consumption Index against the defence and capital goods indices.

The consumption theme offers a wide variety of segments to look for opportunities as it covers broader categories such as retail, automobiles, consumer durables, FMCG, food & beverages, and so on. It also includes real estate proxies such as housing finance, home improvement, etc as well.

While there is much hope on manufacturing, this theme can be highly deceptive if you overlook the key traits that lead to shareholder value creation, return on capital (RoCE). Already, narrative-led themes like chemicals have deceived investors in the recent past.

So even as there is excitement around the manufacturing sector, it makes sense to look at already successful companies and the traits made them succeed in creating value for investors. This has come from sectors like automobiles and pharmaceuticals in the past. Electronics is the new hope. 

For example, in automobiles, consider Bajaj Auto. It has not only utilised the manufacturing economics of India (being a large domestic market), it also developed global markets (presence in 75 countries) and built successful brands - a success story that mirror Japanese auto majors. Each of these factors made up for exceptionally strong competitive advantage, reflecting in its FMCG-like RoCE. 

It is important to take such outstanding enterprises as benchmarks in identifying the drivers of RoCE. Another example would be Eicher Motors and to some extent, TVS Motors. Similarly, in the emerging sectors, Dixon has proved to be an outlier that scores on scale, design (R&D) and customer acquisition (high profile large size global players).  

Infrastructure is another hot theme in markets currently. If we look at this sector over last 20 years, L&T is the only company that has created long term value to shareholders. You will seldom find any other large cap or mid-cap in this space barring GMR and the Adanis. 

For L&T, a big chunk of its current value is represented by its IT services subsidiaries as well. There have been few long-term survivors like KNR Construction and Ahluwalia Construction, but these are still small caps. 

The sector has always been in the limelight in every cycle at the time of order accretion - but few players have successfully navigated the execution and payment cycles without landing into arbitrations. During the order accretion cycle, market prices the stock to perfection based on a certain execution timeline and certain profitability assumption that goes for a toss during other two cycles. 

There is huge fanfare for yesteryear stories in spaces like infrastructure, energy, resources, railways, and so on at this point. There is a saying that “turnarounds rarely turnaround”, but companies that are still leaders in their respective industry with critical product or engineering capabilities could be candidates for it. 

But it is extremely important to check whether the turnarounds have evidence in numbers in terms of debt reduction, better capacity utilisation, margin expansion, business expansion and improving operating cash flows. 

What to do with your equity exposure?

For direct stock investors - stick to key index sectors and stocks in 2024 while hunting for select opportunities outside of index as discussed above to generate extra returns. Focus on the large-cap segment as well. At PrimeInvestor, we will look for stocks along the lines explained above.

For equity mutual fund investors – take this opportunity to check if your portfolio needs rebalancing to trim equity excesses especially in the mid-and-smallcap segments. Continue with SIP (or regular investments) in your equity funds and do not stop or postpone these. The latter half of the year may throw up opportunities to buy on dips, so you can consider maintaining some surplus for investments then.  As we did last year, we may also play sector/thematic opportunities through funds. Do look out for these calls (which will also be housed under Prime Funds) which you can use to play specific opportunities if you wish to.

More like this

7 thoughts on “Prime Equity Outlook 2024”

  1. Do you think that following still holds true or earnings of other companies are also changed? Is Nifty reasonably priced now? Do you want to see earning reports of July to get more details?
    “The higher contribution of earnings from cyclicals limits room for further expansion in PE multiples. Therefore, current valuations at 22 times FY24 earnings and 19 times FY25 estimated earnings are quite fair in our view. “

    1. N V Chandrachoodamani

      Welcome your query sir,

      And this is perhaps the right question at the right time

      As you are aware, we explained about extent of earnings contribution that came from banks, metals, industrials, etc in the report itself to comment on what multiple is fair.

      Interestingly, FY24 was the first year after a long time (excl. Covid years due to volatility) where a double earnings growth for Nifty 50 played out either on expected lines or a tad better than that. Otherwise, every year prior to that, there was a downward revision.

      If we consider the current earnings growth momentum to continue in FY25 (15-16% growth), then Nifty 50 is trading at 20-21 times FY25 earnings (we are now entering Q1 of FY25).

      At this point of time, a 1 PE multiple is equal to 1,000 – 1,150 points in Nifty (as Nifty EPS is 1,000 for FY24, expected at 1,150-1,160 for FY25)

      So, if you assume same 22 PE would sustain for FY25, then it would come close to 25,000-25,300
      (mathematically, no prediction/target, trying to arrive at fair assumption)

      Hope Telecom, metals, cement and power would support Nifty to carry this earnings momentum (15-16%) in FY25 on the back of very high earnings (profit) momentum that we are seeing in those sectors. Again cyclicals doing the job and so PE multiple expansion is not desirable unless the earnings can grow far higher beyond this 15-16%

      In short, from fair pricing, Nifty is moving fast and borrowing “some” returns from future as well.

      A consolidation or correction would be healthy to remove excesses (largely in specific sectors) and lay a healthy foundation for future growth and returns. We can’t call it when as it needs a trigger.

      Right now, markets are bullish globally and banking on “inevitable” rate cuts (that’s what equity markets are assuming).

      A healthy correction should happen form some kind of “dis-appointment” for the market – either on interest rates or Govt. policy shifts or worsening geo-political issues or some unanticipated causes.

      Hope this clarifies

      Thank you

  2. Anandkumar Mehta

    Extremely well written. Well done….I wish everyone good luck in one’s investing journey in 2024

  3. Thank You . A detailed but easy to read article which has info and action points. Kindly share Your views on Geo Political / War Risk. Unlike the period till 2020/21, the threat of war is increasing. How a retail investor, who is mid way towards building retirement corpus, protect his corpus. Will 50:50 Equity – Fixed Income combo will help ? Balaji, Bangalore

    1. Let us try to simplify this. We think it is best not to derail financial goals for such risks. There are only 2 scenarios – one there are such wars that will cause market to crash and eventually factor it in. In which case, you should be using such opportunities to buy. Two, the war kills economies. In which case no asset allocation will help much so there is no point planning for the same 🙂 Vidya

Comments are closed.

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free